• This promotional site is only intended for IRL healthcare professionals. Adverse event reporting can be found at the bottom of the page.

  • Prescribing Information

    • Prescribing Information 

Camzyos Ireland
Obstructive
HCM
About obstructive HCM
Identifying patients
Treatment landscape
Patient profiles
About
CAMZYOS
CAMZYOS MoA
Clinical
Studies
EXPLORER-HCM
VALOR-HCM
EXPLORER-LTE
Efficacy
EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint
EXPLORER-LTE durable efficacy
Safety
Safety profile
Important information
Drug interactions
Dosing
Dosing and initiation
Maintenance and interruption
Special populations
Resources
Prescribing
Information
image
image
Results of your search
0 Results
Clear Filter
Sort by Date
You might also be interested in
/content/buildeasy/europe/camzyos-ie/en.html

foot note heading

Prescribing Information can be accessed using the link on the top right of the page.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety informtation. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie.  Adverse reactions should also be reported to Bristol Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com

BMS-logo

Legal Notice    |    Privacy Policy     |    Cookie Preferences   |  Pharamcovigilance Notice 

© 2025 MyoKardia, Inc., a Bristol-Myers Squibb company. All rights reserved.

3500-IE-2500008  |  February 2026